Report of Foreign Issuer (6-k)
May 08 2019 - 5:06PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16
OR
15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For
the month of May 2019
Commission
File Number: 001-36582
Auris
Medical Holding Ltd.
(Exact
name of registrant as specified in its charter)
Clarendon
House, 2 Church Street
Hamilton
HM 11, Bermuda
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form
20-F ☒ Form 40-F
☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Yes ☐ No ☒
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Yes ☐ No ☒
Annual
General Meeting Results
On
May 8, 2019, Auris Medical Holding Ltd. (the “
Company
”) held its Annual General Meeting of Shareholders (the
“
Meeting
”). The final results of each of the agenda items submitted to a vote of the shareholders are as follows:
Agenda
Item 1: Re-election of the members of the Board of Directors.
The
Company’s shareholders re-elected Thomas Meyer, PhD, Armando Anido, MBA, Mats Peter Blom, MBA, Calvin W. Roberts, MD
and Alain Munoz, MD, as member of the Board of Directors, each for a term of one year ending upon completion of the 2020
Annual General Meeting.
Agenda
Item 2: Re-election of the Auditors
The
Company’s shareholders re-elected Deloitte AG, Switzerland, as auditors of Auris Medical Holding Ltd. for the 2019 financial year.
Agenda
Item 3: Compensation of the Board of Directors and the Executive Management Committee
The
Company’s shareholders approved, on a non-binding advisory basis, the 2018 Board of Directors and executive officers
compensation.
Other Items
At the Meeting, the Chairman informed the
shareholders that going forward the Company, as a Foreign Private Issuer pursuant to the rules and regulations of the Securities
and Exchange Commission (the “SEC”), intends to file financial reports on a semi-annual instead of a quarterly basis
in compliance with such SEC rules. The next financial statements will therefore be filed for the first six months ended June 30,
2019.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
Auris
Medical Holding Ltd.
|
|
|
|
|
|
|
By:
|
/s/
Hernan Levett
|
|
|
|
|
Name:
|
Hernan
Levett
|
|
|
|
|
Title:
|
Chief
Financial Officer
|
Date:
May 8, 2019
2
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
From Sep 2023 to Sep 2024